The market is segmented based on , By Type (Schistosoma Mansoni, Schistosoma Japonicum, Others), Drugs (Praziquantel, Metrifonate, Oxamniquine, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
.
The Global Schistosomiasis Diseases Market size was valued at USD 70.00 USD Million in 2021.
The Global Schistosomiasis Diseases Market is projected to grow at a CAGR of 4% during the forecast period of 2022 to 2029.
The major players operating in the market include Mylan N.V., Teva Pharmaceutical Industries , Sanofi, Pfizer , GSK plc, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Abbvie , AstraZeneca, Johnson & Johnson Private Limited, Cipla , Abbott, Bausch Health Companies , Lupin, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC., Seagen , ONO Pharmaceutical Co., .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Corporate Email ID Only (Avoid Using Generic mail ID such as Gmail)
Consent Preferences
We use cookies to improve your experience We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies. Cookie Notice.
The data presented is for visualization purposes only and may not reflect actual results.
